ArticleThe Clinical biochemist. Reviews2005
Recent developments in the first detection of hepatocellular carcinoma.
Article in The Clinical biochemist. Reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 67 citations in OpenAlex.
- Integrating DNA methylation and gene expression data in a single gene network using the iNETgrate package.Scientific reports · 2023Article
- "iNETgrate": integrating DNA methylation and gene expression data in a single gene network.Research square · 2023Article
- Article
- Cartilage oligomeric matrix protein as a non-invasive biomarker for diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.Gastroenterology and hepatology from bed to bench · 2022Article
- Article
- Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis.Clinical and experimental hepatology · 2018Article
- Article
- Integrative Analysis of Microarray Data to Reveal Regulation Patterns in the Pathogenesis of Hepatocellular Carcinoma.Gut and liver · 2017Article
- Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.World journal of hepatology · 2015Review
- Article
- Field Effect Transistor Biosensor Using Antigen Binding Fragment for Detecting Tumor Marker in Human Serum.Materials (Basel, Switzerland) · 2014Article
- Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients.Molecular biology reports · 2013Article
- Comparative histomorphological review of rat and human hepatocellular proliferative lesions.Journal of toxicologic pathology · 2012Article
- Serine 204 phosphorylation and O-β-GlcNAC interplay of IGFBP-6 as therapeutic indicator to regulate IGF-II functions in viral mediated hepatocellular carcinoma.Virology journal · 2011Article
- Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.World journal of gastroenterology · 2010Article
- Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.Stem cell research · 2010Review
- Contribution of gut bacteria to liver pathobiology.Gastroenterology research and practice · 2010Article
- Intratumoral sampling variability in hepatocellular carcinoma: a case report.World journal of gastroenterology · 2007Article
- Contribution of oncoproteomics to cancer biomarker discovery.Molecular cancer · 2007Review
- Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma.World journal of gastroenterology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) ranks fifth in frequency of cancers worldwide. The main aetiological factor is hepatitis B virus (HBV) although the importance of hepatitis C virus (HCV) is growing. The most important tumour marker for HCC is alpha-fetoprotein (AFP). The common method of screening high risk patients by AFP and ultrasonography has been shown to result in earlier detection and consequently more easily treatable tumours and longer survival. Proposed screening interval varies from once every 3 months to annually to "as indicated' but, most commonly, is once every 6 months. AFP is a fairly specific but insensitive marker for HCC. Sensitivity of HCC detection by blood markers is improved by combining various other markers with AFP. Of the other markers, the newer high sensitivity des-gamma-carboxy-prothrombin (DCP) has been found to be useful. In addition the AFP fractions L3, P4/5 and the +II band are highly specific for HCC. Among routinely assayed tumour markers in the laboratory, CA 125 is more sensitive for HCC than AFP but far less specific. Various other enzymes, isoenzymes, growth factors, adhesion molecules, other proteins such as interleukin-2 receptor (IL-2R), human cervical cancer oncogene protein (HCCR) and glypican-3 (GPC3), p15 and p16 hypermethylation and nitrite/nitrate ratio have been tested; some of these show promise but none is presently in routine use. The value of other newer markers such as the HBx protein that is produced by HBV, and what are thought to be specific proteins and signatures identified by proteomics remain to be determined.
Identifiers
16450014PMC1240033W23602240What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.